Novo Nordisk A/S (NYSE:NVO) Shares Bought by Parkside Financial Bank & Trust

Parkside Financial Bank & Trust grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 28.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,941 shares of the company’s stock after acquiring an additional 435 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Novo Nordisk A/S were worth $201,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of NVO. Pacific Center for Financial Services lifted its holdings in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Copeland Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after buying an additional 141 shares during the period. Bell Investment Advisors Inc lifted its holdings in shares of Novo Nordisk A/S by 79.9% in the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the period. CNB Bank acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at $26,000. Finally, Citizens National Bank Trust Department lifted its holdings in shares of Novo Nordisk A/S by 100.0% in the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on NVO shares. UBS Group started coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Finally, BMO Capital Markets began coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Stock Down 2.4 %

NVO stock traded down $3.04 during mid-day trading on Wednesday, hitting $125.60. The stock had a trading volume of 1,739,540 shares, compared to its average volume of 4,814,228. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a fifty day moving average of $126.66 and a 200 day moving average of $111.54. The stock has a market capitalization of $563.63 billion, a price-to-earnings ratio of 46.42, a PEG ratio of 2.09 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The company had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a dividend of $0.664 per share. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.